Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:CRVS NASDAQ:JANX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$12.14-1.1%$9.48$6.42▼$12.53$1.60B1.231.64 million shs1.68 million shsCRVSCorvus Pharmaceuticals$5.45-1.8%$4.37$2.54▼$10.00$406.10M0.42798,714 shs337,577 shsJANXJanux Therapeutics$23.01-5.3%$24.51$21.97▼$71.71$1.38B2.86939,587 shs528,857 shsWVEWAVE Life Sciences$9.94-2.1%$7.93$5.04▼$16.74$1.58B-0.951.34 million shs1.49 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%0.00%+37.40%+51.86%+81.51%CRVSCorvus Pharmaceuticals0.00%+2.21%+17.83%+59.03%+29.07%JANXJanux Therapeutics0.00%-3.23%-6.39%-3.65%-47.08%WVEWAVE Life Sciences0.00%+4.00%+20.83%+70.59%+76.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.829 of 5 stars1.53.00.00.04.12.52.5CRVSCorvus Pharmaceuticals2.3924 of 5 stars3.52.00.00.00.63.30.6JANXJanux Therapeutics2.965 of 5 stars3.53.00.00.02.73.30.0WVEWAVE Life Sciences4.794 of 5 stars4.51.00.04.83.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$12.00-1.15% DownsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00175.23% UpsideJANXJanux Therapeutics 3.08Buy$86.90277.66% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.27103.89% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, AUPH, WVE, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025JANXJanux TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.008/1/2025AUPHAurinia PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.007/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/30/2025AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.006/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.006/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.00(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$260.11M6.14$0.31 per share39.78$2.68 per share4.53CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AJANXJanux Therapeutics$10.59M130.56N/AN/A$19.49 per share1.18WVEWAVE Life Sciences$93.95M16.84N/AN/A$1.37 per share7.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4328.2321.68N/A23.31%20.06%13.81%11/6/2025 (Estimated)CRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest CRVS, AUPH, WVE, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63CRVSCorvus PharmaceuticalsN/A8.918.91JANXJanux TherapeuticsN/A47.0347.03WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CRVSCorvus Pharmaceuticals46.64%JANXJanux Therapeutics75.39%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CRVSCorvus Pharmaceuticals28.50%JANXJanux Therapeutics29.40%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableCRVSCorvus Pharmaceuticals3074.51 million51.19 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableCRVS, AUPH, WVE, and JANX HeadlinesRecent News About These CompaniesWAVE Life Sciences Ltd. $WVE Shares Sold by Maven Securities LTDAugust 23 at 5:49 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVEAugust 19, 2025 | marketbeat.com29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLCAugust 18, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?August 17, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in StockAugust 15, 2025 | marketbeat.comWave Life Sciences moved to not rated at JPMorganAugust 15, 2025 | msn.comInsider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of StockAugust 14, 2025 | insidertrades.comWave Life Sciences Shareholders Approve Key ProposalsAugust 11, 2025 | msn.comWave Life Sciences Earnings Call: Clinical Advances Amid Financial ChallengesAugust 9, 2025 | theglobeandmail.comKen Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) StockAugust 8, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 SharesAugust 8, 2025 | insidertrades.comWAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity GroupAugust 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management IncAugust 5, 2025 | marketbeat.comCanaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 5, 2025 | msn.comWave Life Sciences is a new Buy at Canaccord Genuity on near-term catalystsAugust 5, 2025 | msn.comB. Riley Reduces Earnings Estimates for WAVE Life SciencesAugust 4, 2025 | marketbeat.comFY2025 Earnings Forecast for WVE Issued By Cantor FitzgeraldAugust 4, 2025 | marketbeat.comResearch Analysts Issue Forecasts for WVE FY2025 EarningsAugust 4, 2025 | marketbeat.comQ3 EPS Forecast for WAVE Life Sciences Reduced by AnalystAugust 4, 2025 | marketbeat.comQ3 EPS Estimates for WAVE Life Sciences Decreased by WedbushAugust 4, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 6.3% Higher - Here's WhyAugust 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, AUPH, WVE, and JANX Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$12.14 -0.13 (-1.06%) Closing price 04:00 PM EasternExtended Trading$12.22 +0.08 (+0.70%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Corvus Pharmaceuticals NASDAQ:CRVS$5.45 -0.10 (-1.80%) Closing price 04:00 PM EasternExtended Trading$5.45 0.00 (0.00%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Janux Therapeutics NASDAQ:JANX$23.01 -1.29 (-5.31%) Closing price 04:00 PM EasternExtended Trading$23.50 +0.49 (+2.13%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.WAVE Life Sciences NASDAQ:WVE$9.94 -0.21 (-2.07%) Closing price 04:00 PM EasternExtended Trading$10.00 +0.06 (+0.59%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Why Zuckerberg's META Sales Look More Bullish Than Bearish 3 Dividend Growth Leaders to Buy Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access